SEC Form 4 · accession 0001209191-17-062387
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Bodick
Officer — Chief Scientific Officer
Period of report
Nov 21, 2017
Accepted (ET)
Nov 22, 2017 · 5:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 21, 2017 | P | 1,700 | $24.3862 | A | 64,605 | D | |
| Common Stock | Nov 21, 2017 | P | 1,000 | $24.6557 | A | 1,000 | I | By Spouse |
| Common StockF1 | holding | — | — | — | 388,683 | I | By Versant Development Fund III, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.